##### 



*** Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4)
And 240.24b-2
 Exhibit 10.100
 DEVELOPMENT AGREEMENT  FOR PANTHER INSTRUMENT SYSTEM
 THIS AGREEMENT
 WHEREAS
 WHEREAS In Vitro
 WHEREAS
 WHEREAS
 NOW, THEREFORE
 1 of 35




---



##### 



ARTICLE 1  DEFINITIONS
 1.1 Acceptance Criteria
 1.2 Affiliate
 1.3 Agreement
 1.4 Cancellation Charges [***]
  2 of 35




---



##### 



1.5 Change Control
 1.6 Currency
 1.7 Designated Project Members
 1.8 Gen-Probe IP Rights  provided further
 3 of 35




---



##### 



1.9 GMP 
 1.10 Know-How
 1.11 New Technology
 1.12 Payment
 1.13 Panther
 4 of 35




---



##### 



1.14 Panther Prototypes
 1.15 Panther Validation Instruments
 1.16 Pre-Production Instruments
 1.17 Pre-Existing Gen-Probe Technology 
 5 of 35




---



##### 



1.18 Pre-Existing STRATEC Technology
 1.19 Program Material [***]
 1.20 Project Parameters
  6 of 35




---



##### 



1.21 Reliability Requirements
 1.22 Shipping Criteria
 1.23 Steering Committee 
 7 of 35




---



##### 



1.24 STRATEC IP Rights 
 1.25 Training
 ARTICLE 2  DEVELOPMENT AND ADAPTATION, PAYMENTS, TERMINATION
 2.1 Development and Adaptation Activities
 a.
 b.
 c.
 8 of 35




---



##### 



d.
 9 of 35




---



##### 



e. QSR GMPs
 2.2 Payments by Gen-Probe
 a.
 10 of 35




---



##### 



PAYMENT SCHEDULE
 MS
    
    Phases
    
    Development Milestone
    
    Payment1
    
    0
    
    Execution of Agreement
    
    
    [***]2
    
    1
    
    Completion of phase 1 and mutual sign-off of PRD including Shipping and Acceptance Criteria
    
    
    [***]3
    
    2a
    
    Gen-Probes written authorization for STRATEC to commence Phase 2 activities
    
    
    [***]4
    
    2a
    
    Delivery of Panther Prototypes
    
    
    [***]5
    
    2a
    
    Acceptance of Panther Prototypes
    
    
    [***]6
    
    2b
    
    Delivery of Panther Validation Instruments
    
    
    [***]7
    
    2b
    
    Acceptance of Panther Validation Instruments
    
    
    [***]8
    
    3
    
    Release for manufacturing
    
    
    [***]US$
    6,270,000.00
  b.
 c. Milestones 1, 2 and 3:
 d. Milestone 4:
  11 of 35




---



##### 



e. Milestone 5:
 f. Milestone 6:
 12 of 35




---



##### 



g. Milestone 7:
 h. Milestone 8:
 i.
 13 of 35




---



##### 



j.
 2.3 Communication and Changes to Project Parameters
 a.
 b.
 14 of 35




---



##### 



c.
  [***] [***]
  15 of 35




---



##### 



d.
 2.4 Training
 a.
 b.
 16 of 35




---



##### 



2.5 Shipping
 a. Delivery
 b. Shipping Instructions
 c. Shipping Containers
 d. Title
 e. Damage Claims
 17 of 35




---



##### 



2.6 Termination and Activities After Termination 
 a. Termination for Insolvency
 b. Termination for Breach
 c. Gen-Probe Termination Right provided, however, [***] [***] [***]
  18 of 35




---



##### 



2.7 Continued Development 
 Continued Development of Panther
 Portal Access and Escrow
 ARTICLE 3  PURCHASE OF TOOLING, PROTOTYPE INSTRUMENTS AND  VALIDATION INSTRUMENTS
 3.1 Purchase of Panther Tooling 
 19 of 35




---



##### 



[***] [***]
 3.2 Procurement of Panther units under this Development
Agreement
  
    
    up to [***]Panther Prototypes at a transfer price of [***]per unit, [***].
Two of these Panther Prototype units shall be Gen-Probes property but remain at
STRATEC until the end of the development program. The total number of Panther
Prototypes to be ordered shall be mutually agreed upon no later than at the end of
Phase 1.
    
    Up to [***]Panther Validation Instruments (validation units in STRATECs
terminology) at a transfer price of [***]. Four of these Panther Validation Instruments
shall be Gen-Probes property but remain at STRATEC until the end of the development
program. The total number of Panther Validation Instruments to be ordered shall be
mutually agreed upon no later than at the end of Phase 1.
 [***] [***]
 
    
    The parties will use reasonable efforts to implement a cost reduction
program which may reduce the transfer prices set forth above.
    
    Gen-Probe may request delivery of reasonable quantities of additional
Prototype, Validation, and Pre-Production Instruments. STRATEC shall not unreasonably
withhold its consent to such request. The parties shall reasonably negotiate any
  20 of 35




---



##### 



price changes based on changes in STRATECs costs for the additional instruments.
 3.3 Taxes
 3.4 Manufacture of Panther
 21 of 35




---



##### 



ARTICLE 4  PROPRIETARY RIGHTS
 4.1 Freedom to Use provided ,
however,
 22 of 35




---



##### 



4.2 IP Rights Relating to Existing Components
 a.
 b.
  [***]
   23 of 35




---



##### 



4.3 IP Rights Relating to New Technology
 a.
 b. [***]
 c. [***] [***] [***] [***]
 24 of 35




---



##### 



d.
 e.
 4.4 Gen-Probe Ownership of Software and Design
 4.5 Invention Disclosure
 25 of 35




---



##### 



4.6 Use of Know-How
 4.7 Enforcement
 a.
 b.
 ARTICLE 5  CONFIDENTIALITY
 5.1 Confidential Information
 26 of 35




---



##### 



5.2 Subcontractors
 5.3 Standard of Care
 5.4 Extension of Obligations
 ARTICLE 6  COMMERCIAL TERMS
 6.1 Conflicting Documents
 6.2 STRATEC Warranty and Representations
 27 of 35




---



##### 



6.3 Indemnification
 a.
    
    Indemnification by STRATEC.
   28 of 35




---



##### 



b Indemnification by Gen-Probe .
 Limitations of Warranties
 29 of 35




---



##### 



ARTICLE 7  MISCELLANEOUS PROVISIONS
 7.1 Interpretation
 vice versa
    30 of 35




---



##### 



7.2 Rights of Inspection and Audit
 7.3 Official Correspondents
 7.4 Independent Contractors
 7.5 Notices
 31 of 35




---



##### 



If to Gen-Probe:
    
    Gen-Probe Incorporated10210 Genetic Center DriveSan Diego, California 92121USAAttention: Chief Executive OfficerCopy to: General CounselIf to STRATEC:
    
    STRATEC Biomedical Systems AGGewerbestrasse 37D-75217 BirkenfeldGermanyAttention: Vorstand / Board of ManagementCopy to: Rechtsabteilung / Law and Patents
 7.6 Compliance with Relevant Laws
 7.7 Adverse Information
 7.8 Noninterference
 7.9 Assignments, Succession and Waivers
 32 of 35




---



##### 



7.10 Unforeseen Circumstances
 7.11 Integration
 7.12 Publication
 33 of 35




---



##### 



7.13 Governing Law
 7.14 Legal Counsel
 7.15 Severability
 7.16 Non-Waiver
 7.17 Arbitration 
 34 of 35




---



##### 



7.18 Headings
 7.19 Survivability
 7.20 Multiple Executions
 IN WITNESS WHEREOF
 Gen-Probe Incorporated
    
    STRATEC Biomedical Systems AGBy
/s/ Niall Conway
    
    By /s/ Hermann LeistnerNiall Conway
    
    Hermann LeistnerExecutive Vice President, Operations
    
    Chairman, Board of ManagementBy
/s/ R. William BowenR. William BowenVice President & General CounselDate:
22 November 2006
    
    Date: 22 November 2006
 35 of 35